Show simple item record

Metallothionein levels in ovarian tumours before and after chemotherapy.

dc.contributor.authorMurphy, D
dc.contributor.authorMcGown, Alan T
dc.contributor.authorCrowther, Derek
dc.contributor.authorMander, A
dc.contributor.authorFox, Brian W
dc.date.accessioned2010-07-27T15:53:08Z
dc.date.available2010-07-27T15:53:08Z
dc.date.issued1991-05
dc.identifier.citationMetallothionein levels in ovarian tumours before and after chemotherapy. 1991, 63 (5):711-4 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid2039697
dc.identifier.urihttp://hdl.handle.net/10541/108464
dc.description.abstractThe metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCyclophosphamide
dc.subject.meshDoxorubicin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIfosfamide
dc.subject.meshMelphalan
dc.subject.meshMetallothionein
dc.subject.meshMiddle Aged
dc.subject.meshOvarian Neoplasms
dc.subject.meshOvary
dc.titleMetallothionein levels in ovarian tumours before and after chemotherapy.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThe metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.


This item appears in the following Collection(s)

Show simple item record